Cellyan Biotechnology Co., Ltd HKPD
Annual
Quarterly
FY2025 · ended Mar 31, 2025 · Revenue $20.31M · Filed Aug 14, 2025
Cellyan Biotechnology Co., Ltd (HKPD) files with the SEC under industry code 5122, Wholesale-Drugs, Proprietaries & Druggists' Sundries. In fiscal 2025, which ended Mar 31, 2025, it reported revenue of $20.3 million and a net loss of $27,056. Free cash flow was $499,298. As of Mar 31, 2025 it held $748,721 in cash and investments and $2.4 million in total debt.
Revenue
$20.31M
Net income
$-27,056
Operating cash flow
$569,214
Free cash flow
$499,298
EPS
$-0.00
Dividend per share
None
Shares outstanding
16.35M
+48.6% vs prior year
Net cash
$-1.63M
FY 2025
Operating margin
-11.2%
FY 2025
Company profile
- Industry
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (SIC 5122)
- Listed as
- HKPD (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- Cayman Islands
- Headquarters
- Kowloon
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 2007702
- Former names
- Hong Kong Pharma Digital Technology Holdings Ltd (until Dec 17, 2025)
Other Wholesale-Drugs, Proprietaries & Druggists' Sundries companies
- Mckesson Corp MCK
- Cencora, Inc. COR
- Cardinal Health Inc CAH
- Herbalife Ltd. HLF
- Nu Skin Enterprises, Inc. NUS
- EnerSyn Global Inc. ESYN
- Cosmos Health Inc. COSM
- DataMeds AI, Inc. MEDS
All 11 Wholesale-Drugs, Proprietaries & Druggists' Sundries companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Mar 31, 2025 |
|---|---|
| Revenue | $20.3M |
| Operating income | -$2.3M |
| Net income | -$27,056 |
| Diluted EPS | -$0.00 |
| Operating cash flow | $569,214 |
| Free cash flow | $499,298 |
| Total assets | $9.4M |
| Total liabilities | $4.4M |
| Stockholders' equity | $5.0M |
| Cash and investments | $748,721 |
| Total debt | $2.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 21, 2026 | Oct 21, 2026 |
| 6-K | Current report (foreign issuer) | Sep 24, 2026 | Sep 23, 2026 |
| 6-K | Current report (foreign issuer) | Sep 23, 2026 | Sep 23, 2026 |
| 6-K | Current report (foreign issuer) | Sep 10, 2026 | Sep 9, 2026 |
| 20-F | Annual report (foreign issuer) | Aug 7, 2026 | Mar 31, 2026 |
| 6-K | Current report (foreign issuer) | Jul 16, 2026 | Jul 16, 2026 |
All 67 Cellyan Biotechnology Co., Ltd SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.